Novo Nordisk A/S - Share repurchase programme
On 15 August 2008 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an
amount of up to DKK 1.7 billion in the period from 15 August 2008 to
19 December 2008.
Since the announcement as of 10 November 2008, the following
transactions have been made under the programme:
Number of Average Transaction
shares purchase price value, DKK
Accumulated, last
announcement 3,376,500 956,623,504
10 November 2008 50,000 307.8600 15,393,000
11 November 2008 50,000 304.0800 15,204,000
12 November 2008 50,000 305.3800 15,269,000
13 November 2008 50,000 297.9500 14,897,500
14 November 2008 50,000 297.2600 14,863,000
Accumulated under
the programme 3,626,500 1,032,250,004
Transactions related to Novo Nordisk's incentive programmes have
resulted in a net sale by Novo Nordisk of 83,305 B-shares in the
period from 10 November 2008 to 14 November 2008. The shares in these
transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of
24,593,285 treasury shares, corresponding to 3.9% of the share
capital. The total amount of shares in the company is 634,000,000
including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,550
employees in 80 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Further information:
Media: Investors:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: Kasper Roseeuw Poulsen
Sean Clements Tel: (+45) 4442 4471
Tel: (+1) 609 514 8316 krop@novonordisk.com
secl@novonordisk.com
Company Announcement no 75 / 2008
